Abstract Background and purpose: The role of Epstein-Barr virus (EBV) in breast carcinogenesis is still controversial. Unraveling this relationship is potentially important for better understanding of breast cancer etiology, early detection and possibly prevention of breast cancer. The aim of the current study is to unravel the association between EBV and primary invasive breast cancer (PIBC) in two different Arab populations (Egyptian and Iraqi women). Patients and Methods: The study was done on paraffin-embedded tissues of 40 Egyptian and 50 Iraqi patients with PIBC in addition to 20 normal breast tissues as controls for each group. Both controls and neoplastic tissues were assessed for the expression of EBV genes and proteins (EBNA-1, LMP-1, and EBER) as well as CD21 marker by immunohistochemistry (IHC), in situ hybridization (ISH) and PCR techniques. Results: Our gold standard for EBV reactivity in breast cancer cases was positivity of both EBNA1 by PCR and EBER by in situ hybridization. EBV was detected in 18/40 (45%) and 14/50 (28%) of Egyptian and Iraqi women; respectively where p = 0.073, compared to 0/20 (0%) of their control groups (p < 0.05). Regarding the association between EBV positivity and tumor grade, there was not any statistical significant difference between EBV presence and tumor grade in both populations * Corresponding author. Tel.: +20 101413521; fax: +20 223644720. E-mail address: ncizekri@yahoo.com (A.-R.N. Zekri). Peer review under responsibility of The National Cancer Institute, Cairo University.
Abstract Background and purpose: The role of Epstein-Barr virus (EBV) in breast carcinogenesis is still controversial. Unraveling this relationship is potentially important for better understanding of breast cancer etiology, early detection and possibly prevention of breast cancer. The aim of the current study is to unravel the association between EBV and primary invasive breast cancer (PIBC) in two different Arab populations (Egyptian and Iraqi women). Patients and Methods: The study was done on paraffin-embedded tissues of 40 Egyptian and 50 Iraqi patients with PIBC in addition to 20 normal breast tissues as controls for each group. Both controls and neoplastic tissues were assessed for the expression of EBV genes and proteins (EBNA-1, LMP-1, and EBER) as well as CD21 marker by immunohistochemistry (IHC), in situ hybridization (ISH) and PCR techniques. Results: Our gold standard for EBV reactivity in breast cancer cases was positivity of both EBNA1 by PCR and EBER by in situ hybridization. EBV was detected in 18/40 (45%) and 14/50 (28%) of Egyptian and Iraqi women; respectively where p = 0.073, compared to 0/20 (0%) of their control groups (p < 0.05). Regarding the association between EBV positivity and tumor grade, there was not any statistical significant difference between EBV presence and tumor grade in both populations
Introduction
Breast cancer is the most frequently diagnosed malignancy of women in many populations [1] . In Egypt, breast cancer ranked first among all tumors presented to the National Cancer Institute (NCI), Cairo, where it represents 17.5% of all diagnosed cancer cases [2] . Researches into breast cancer etiology have focused primarily on reproductive and other factors affecting circulating sex hormones and on genetic susceptibility. However, as identified risk factors are thought to explain the incidence in about half of all breast cancer cases only, researchers are motivated to consider other routes for disease pathogenesis [3] [4] [5] [6] . Viruses have been implicated in the development of various cancers, but they have not been much considered for breast cancer. Identification of the mouse mammary tumor virus (MMTV) supports a viral etiology for breast tumors in animals, though similar germ line viral sequences found in humans are not believed to play any direct role in carcinogenesis [7] . Detection of Epstein-Barr virus (EBV) in the neoplastic tissues of breast cancer cases has been reported by some authors [8] [9] [10] [11] [12] [13] . The relationship between breast cancer and EBV could be of potential importance not only for better understanding of breast cancer etiology, but also for early detection, prevention of breast cancer and treatment. A possible association of EBV with breast cancer was proposed as a consequence of the high incidence of male breast cancers, which was reported in Mediterranean countries, an area endemic for EBV; also, the occurrence of some EBVassociated lymphomas in the breast, and the morphological similarities between medullary carcinoma of the breast and nasopharyngeal carcinoma (NPC) [14] . EBV sequences were found in breast tissues and milk, and transfection of p31 fragment of EBV DNA has been shown to immortalize epithelial cells including mammary epithelial cells [1] . Furthermore, it has been reported that breast cancer cells are heterogeneous in terms of EBV genome content and distribution and this raises the possibility that even though EBV might have no etiological role, it can still contribute to tumor development [14] .
Most of the studies performed to date to assess the association between EBV infection and breast carcinoma have been done in Western countries, however, consistent results have to be demonstrated from studies conducted all over the world in order to establish a causal relationship. So far, few studies have been reported from Asian countries [13, 15, 16] and from Egypt [17] [18] [19] . In the current study, a combined approach has been applied to overcome the limitation of commonly used methods for EBV detection in breast cancer, which have lymphocytic infiltrates. Each patient was screened for EBNA1 presence by PCR followed by EBER by in situ hybridization (ISH) to localize the EBV and then LMP1gene was amplified by PCR. Also, CD21 detection by IHC was done in order to localize and target EBV receptors. Therefore, our study was conducted to determine the possible relation between EBV infection and primary invasive breast carcinoma (PIBC) cases in two different Arab populations; Egyptian and Iraqi patients; also, to assess the geographic variability as seen in other malignancies associated with EBV.
Patients and methods

Patients and tissue specimens
This study was done on 40 Egyptian and 50 Iraqi patients with PIBC, in addition to 20 normal breast tissue samples from each country as a control group. All patients were newly diagnosed and none of them had a previous history of breast carcinoma or any other malignancy. Paraffin blocks of breast tissues were obtained from the Pathology Departments of the National Cancer Institute, Cairo University, Egypt, from January 2010 to September 2010 and at the same period, from Baghdad Medical College, Baghdad University, Iraq. For each tumor block, five (4l thick sections) were cut onto positivecharged slides for routine histopathological examination, immunohistochemistry (IHC) and in situ hybridization (ISH). Another five (10l thick sections) were cut into a sterile Eppendorf tube for subsequent DNA extraction. A written consent was obtained from all patients prior to enrollment in the study, and the ethical committees of the NCI and Baghdad University approved the protocol, which was in accordance with the ethical guidelines of the 2008 Declaration of Helsinki.
EBER in situ hybridization (ISH)
In situ hybridization for the detection of EBV-specific RNAs (EBER) was performed using kits from Dako, Glostrup, Denmark. Samples were analyzed by microscopy for EBERstained nuclei. Sections from EBV-positive nasopharyngeal carcinoma were used as positive controls.
Immunohistochemistry
The standard streptavidirin-biotin-peroxidase detection technique was performed as previously described [20] using the mouse monoclonal antibody for CD21 (CD21 A-3, Santa Cruz biotechnology, California, USA) against EBV membrane receptor and LMP-1 (Santa Cruz biotechnology, California, USA). The antigen retrieval method was performed by microwave pretreatment in 0.01 M citrate buffer (pH 6.0). Manufacturer's protocols were followed for all procedures. The primary antibody was applied and incubated overnight at 4°C in a humidified chamber and after 3 washes in PBS, the secondary antibody and the avidin-biotin complex (ABC) were applied to slides. Diaminobenzidine (DAB) was used as a chromogen and sections were counterstained using Mayer's hematoxylin. To evaluate the specificity of the antibodies, known positive and negative tissues were used as controls. Assessment of CD21 was based on a membranous or membrano-cytoplasmic pattern. Cases were considered positive with >10% stained cells.
DNA extraction
High molecular weight DNA was extracted from the paraffin sections according to standard protocols. Briefly, samples were de-waxed twice with 1 mL xylene for 10 min, washed twice with 100% ethanol, dried and re-suspended in 500 ll PK buffer [50 mmol/L KCl, 10 mmol/LTris-HCl (pH8.3), 2.5 mmol/ L MgCl2, 100 lg/mL gelatin, 0.45% Tween20] and 100 lg/ mL proteinase K. Samples were digested overnight at 55°C, extracted with phenol: chloroform: isoamyl, ethanol precipitated. Nucleic acid was dissolved in 100 lL TE storage buffer.
Polymerase chain reaction (PCR)
Tumor and normal DNA were used for PCR, which was done to detect EBNA-1 and LMP-1 expression as previously described by Hashimoto et al. [21] . PCR products were electrophoresed in 2% ethidium bromide-stained agarose gel and visualized with UV light transilluminator ( Fig. 1 ).
Statistical analysis
Statistical analyses were carried out using a program of statistical package for social sciences (SPSS) version 18 (PASW IBM Corp., USA, 2010). Numerical data (age) were presented as mean ± standard deviation (SD) or median and range. Qualitative variables, such as EBV viral markers' presence and clinicopathological features for Egyptian and Iraqi patients, were expressed by frequencies and percentage. Comparison between age groups for Egyptian and Iraqi cases was done using the t-test as appropriate. Differences between Egyptian and Iraqi EBV-Positive Breast Carcinomas with regard to clinicopathological features were examined using either Chisquare test (v2) or Fisher's exact test when appropriate. Rank biserial correlation coefficient was calculated for studying the strength of association between ordinal variable (tumor grade) and nominal variable (EBV presence). p-value <0.05 was considered significant.
Results
EBV positivity in breast cancer cases
Our gold standard for EBV positivity in breast cancer cases was the detection of EBNA1 antigen by PCR and EBER1 by in situ-hybridization assay. We performed EBER in situ hybridization on the PCR positive cases to localize the positive signal. PCR-Egyptian positive cases were 23/40(57.5%). Out of those 23 patients, 18(45%) cases were positive for EBER (ISH). From those 18 patients, 12(30%) cases were positive for LMP1 (PCR), as illustrated in Fig. 1 . Detection of LMP1 antigen by PCR method can distinguish the latent EBV from non-latent infection that was confirmed by the presence of EBV by immunohistochemistry technique in the breast cancer tissues, as shown in Fig. 2 . On the other hand, PCRIraqi positive cases were 16/50(32%). Out of those 16 patients, 14(28%) cases were positive for EBER (ISH), and 11(22%) cases were positive for LMP1 (PCR). In other words, 11 Iraqi patients had EBV latent infection. Also, CD21 detection by IHC was done in order to localize and target EBV receptors, where it was found in 22/40(55%) and 16/50(32%) of Egyptian and Iraqi patients, respectively. Table 1 shows the frequency of different EBV markers by each technique (LMP1 and EBNA1 by PCR or EBER by ISH, or CD21 by IHC) in the Egyptian and Iraqi groups in addition to their controls. The highest frequency was reported using EBNA-1 PCR assay, where it was positive in 57.5% Egyptian patients. However, the lowest prevalence was reported using LMP1 by PCR assay in 22% of Iraqi patients.
Our results demonstrated that EBV positivity in PIBC tissues was (45%) and (28%) in Egyptian and Iraqi patients respectively (Table 2) , while it was absent in the control group 0/20(0%) of both populations. There was a highly statistically significant difference between the prevalence of EBV in tumor and normal tissue samples in both populations (p = 0.0001 and p = 0.005 for Egyptian and Iraqi cases, respectively). Table 2) .
Relationship of EBV reactivity with pathological features
Regarding the association between EBV positivity and tumor grade, there was not any statistical significant difference between EBV presence and tumor grade in both populations where p = 0.860 and p = 0.976, and the calculated rank biserial correlation coefficient was 0.114 and 0.269 for Egyptian and Iraqi women respectively.
Discussion
EBV was classified as a group-1 carcinogen by IARC Working Group [22] . However, the associated cancers vary markedly in viral prevalence, from nearly 100% of nasopharyngeal carcinoma (NPCs) to about 10% of gastric carcinomas [23] [24] [25] , and also differ in the patterns of viral genes expressed, suggesting that EBV may affect cell growth in more than one way [25] . Thus, EBV infection represents an important but not a sufficient step in carcinogenesis, and epidemiological risk factors have been shown to play an additional critical role in this process. Indirect support for an association of EBV with breast cancer comes from observations that: (a) EBV is present in breast tissue, where it is detected in breast milk in some women [26] ; (b) transfection of EBV DNA stimulates growth of human breast milk cells [27] ; (c) some EBV-associated lymphomas occur in the breast [28, 29] ; (d) breast cancer has epidemiological similarities to young-adult Hodgkin's lymphoma, although evidence for breast cancer implicates timing of primary EBV infection rather than viral oncogenesis [30] ; (e) EBV has been identified in benign breast tumors in immunosuppressed women [31] ; (f) in vitro, breast epithelial cells can be infected by direct contact with EBV-bearing lymphoblastoid cell lines [32] ; and (g) Regarding serological evidence, measurement levels of anti-EBNA-1 Immunoglobulin (IgG) antibodies in stored sera of Breast Cancer Indian Women was previously done by Joshi et al. [13] using commercial Enzyme linked Immunosorbent Assay (ELISA) kit, in which patients with benign breast diseases were used as a comparison group for both immunohistochemical and serological analysis. In the current study, multiple analytical assays have been used for evaluation of different EBV gene products under study. First assay was In situ Hybridization for EBER detection where it enables us for differentiating EBV in tumor cells from EBV in surrounding lymphocytes. Second and third assays were PCR for amplification of EBNA-1 and LMP-1 detection where PCR is potentially a highly sensitive and specific method but it cannot differentiate EBV in malignant breast epithelial cells from EBV in surrounding lymphocytes. The fourth assay was Immunohistochemistry for CD21 detection in order to localize and target EBV receptors.
Our results have shown that EBV positivity in PIBC tissues was (45%) and (28%) in Egyptian and Iraqi patients respectively. This observation may be explained by the fact that EBV DNA presence in breast cancer patients can differ between groups with different demographic distributions and population characteristics, as stated by Wiencke [33] . In other words, distribution of HLAs may differ in Egyptian population than in Iraqi population. However, because of the numbers of samples tested, these observations should be confirmed in population-based studies involving larger numbers of samples.
In addition, EBV detection was absent in the control group of both populations (p < 0.05), where the normal breast tissues were obtained from different normal subjects. Although most of the previous studies have used normal breast tissues distant to tumor, we preferred to assess EBV in normal breast tissues obtained from reduction mammoplasty specimens for two reasons. First, several previous studies on different solid tumor types provided evidence that what is called adjacent normal tissues is only morphologically normal since many molecular changes have been detected in these areas. Second, in most breast cancer cases the adjacent normal tissues contain many inflammatory cells and lymphocytes which are the normal reservoir for EBV and this could affect the final results [34] [35] .
This finding is in close to the previous study done by Joshi et al. [13] where they found that about 55% of breast cancer Indian women cases showed EBNA-1 expression in tumor cells by IHC, while all the controls with benign breast disease were negative. Also, two Egyptian authors Mohamed et al. [18] and Fawzy et al. [19] have reported EBV infection in 35.3% and 25% of invasive breast carcinoma respectively; however, those three studies had certain limitations, where they looked for expression of only one viral protein. They should have investigated multiple EBV proteins present in different phases of viral latency seen in other EBV associated tumors. Also, our findings are close to numerous studies done by Horiuchi et al. [36] , Luqmani and Shousha [8] , Labrecque et al. [9] , Bonnet et al. [12] , Brink et al. [37] , Fina et al. [38] , Grinstein et al. [39] , Xue et al. [27] , Preciado, [40] , Perkins et al. [41] , and Lorenzetti et al. [42] , where EBV infection has been found most consistently and in a prevalence of about 10-50% using PCR method, and histochemical methods have produced evidence of viral DNA or proteins within the breast cancer cells that suggests a pathogenic role of EBV. Although EBV infection has been found by several authors, it has been completely undetected by others such as Gaffey et al. [43] , Lespagnard et al. [44] , Glaser et al. [11] , Dadmanesh et al. [45] , and Kijima et al. [46] , as illustrated in Table 3 . The inconsistency and apparent variability of these findings should not itself exclude a role of EBV in breast carcinogenesis because it is influenced to some extent by three issues: First, the marked variation in EBV prevalence even among studies using the similar techniques as the studies done by Bonnet et al. [12] , Brink et al. [37] , and Deshpande et al. [51] ; Second, the possibility of false-positive or -negative analytical test results due to lymphocyte-derived EBV, cross-reactivity immunostains, amplicon contamination, or inappropriate technique sensitivity; and the last issue is the absence of EBV-cancer association hallmarks including EBERs expression in all cells of virus-associated tumors. Breast cancer may express EBERs less abundantly than other malignancies [9] [10] [11] [12] . However, EBERs are not found in all NPCs or in some Burkitt and Hodgkin lymphomas that are LMP-1 positive by PCR [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
Regarding the association of EBV presence with tumor grade, there was no statistical significant relation between EBV presence and tumor grade (p > 0.05) in both populations. The correlation coefficient indicates a weak correlation where it was 0.114 and 0.269 for Egyptian and Iraqi patients respectively. This finding disagrees with that done by Mazouni et al. [50] where they stated that the proportion of EBV-positive samples increased significantly with increasing tumor grade, from 16.2% for grade I, to 32.0% and 46.4% for grades II and III, respectively. The inconsistency in both results might be due to; (a) the small sample size where our study was done on 40 Egyptian and 50 Iraqi patients compared to 196 French breast tumor cases, and (b) the various laboratory methods that were applied in our study for assessment of EBV genes and proteins (immunohistochemistry (IHC), in situ hybridization (ISH) and PCR), while real time PCR assay has been used by Mazouni et al. [52] for EBV detection.
In conclusion, our findings suggest that EBV might have a role in the pathogenesis of breast cancer. These findings were based mainly on EBV detection by PCR technique and confirmed by immunohistochemistry and in situ hybridization techniques in breast cancer patients from different geographic region. So, EBV may contribute to increased tumor aggression even in patients from different geographic region.
Further research is necessary in order to determine the role of EBV in the etiology or progression of breast cancer, particularly; it was detected in the lymphocytes around the breast tissues suggesting its contribution as a modulating agent in the microenvironment area around those breast tissues. In other words, it may modulate the secretion of interleukin-6 and tumor necrosis factor which have proven to have a role in breast cancer development.
